Maravai LifeSciences Sees Unusually High Options Volume (NASDAQ:MRVI)

Key Points

• Unusually large put activity: Traders purchased 1,002 put options on MRVI—an increase of 1,791% versus the typical volume of 53—signaling heavy bearish/options hedging interest in the stock.
• Insider buy: Director Gregory T. Lucier acquired 51,472 shares at $3.70, increasing his ownership by 93.38% to 106,595 shares; corporate insiders hold 2.11% of the stock.
• Institutional and analyst backdrop: Institutions now own 50.25% after large additions from Tejara Capital and Monaco Asset Management, analysts have a consensus "Hold" with a $4.86 target, and the stock recently traded around $3.68 (down 3.7%).

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Traders purchased 1,002 put options on the stock. This is an increase of 1,791% compared to the typical volume of 53 put options.

Insider Transactions at Maravai LifeSciences

In other news, Director Gregory T. Lucier acquired 51,472 shares of Maravai LifeSciences stock in a transaction that occurred on Friday, December 5th. The stock was purchased at an average price of $3.70 per share, for a total transaction of $190,446.40. Following the completion of the transaction, the director directly owned 106,595 shares in the company, valued at approximately $394,401.50. This trade represents a 93.38% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 2.11% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Maravai LifeSciences

A number of institutional investors have recently added to or reduced their stakes in MRVI. Tejara Capital Ltd grew its holdings in Maravai LifeSciences by 26.4% during the third quarter. Tejara Capital Ltd now owns 2,453,441 shares of the company's stock worth $7,041,000 after acquiring an additional 511,992 shares during the period. Monaco Asset Management SAM grew its stake in shares of Maravai LifeSciences by 315.0% in the 3rd quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company's stock worth $10,494,000 after purchasing an additional 2,775,372 shares during the last quarter. Bank of Montreal Can bought a new stake in shares of Maravai LifeSciences in the 2nd quarter worth approximately $72,000. Immersion Corp raised its holdings in shares of Maravai LifeSciences by 153.3% in the 2nd quarter. Immersion Corp now owns 990,000 shares of the company's stock worth $2,388,000 after purchasing an additional 599,164 shares in the last quarter. Finally, Harspring Capital Management LLC acquired a new stake in Maravai LifeSciences during the second quarter valued at approximately $1,205,000. 50.25% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently weighed in on the company. Wall Street Zen upgraded Maravai LifeSciences from a "sell" rating to a "hold" rating in a research note on Saturday, February 28th. Wells Fargo & Company lifted their price target on shares of Maravai LifeSciences from $4.00 to $4.50 and gave the company an "overweight" rating in a research report on Monday, December 15th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Maravai LifeSciences currently has an average rating of "Hold" and a consensus target price of $4.86.

Maravai LifeSciences Stock Down 3.7%

Shares of MRVI stock traded down $0.14 on Thursday, hitting $3.68. The stock had a trading volume of 298,294 shares, compared to its average volume of 1,128,547. Maravai LifeSciences has a 52-week low of $1.66 and a 52-week high of $4.11. The firm has a market capitalization of $941.01 million, a price-to-earnings ratio of -4.09 and a beta of 0.38. The company has a debt-to-equity ratio of 0.85, a quick ratio of 5.69 and a current ratio of 6.60. The stock's 50 day moving average is $3.46 and its 200-day moving average is $3.23.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.03. Maravai LifeSciences had a negative net margin of 70.40% and a negative return on equity of 22.79%. The company had revenue of $49.87 million during the quarter, compared to analyst estimates of $49.06 million. As a group, research analysts expect that Maravai LifeSciences will post -0.24 earnings per share for the current year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc NASDAQ: MRVI is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company's offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai's platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.